C50
Conditions
Interventions
Group 1: 199 breast cancer patients undergo combined whole-body 18F-FDG-MR-PET and the standard staging procedure according to the guideline: interdisziplinären S3-Leitlinie für die Diagnostik, Therap
Sponsors
Universitätsklinikum Düsseldorf, Institut für Diagnostische und Interventionelle Radiologie
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: female sex, newly diagnosed locally advanced therapy naive breast cancer Tumor stage T2-T4 or triple-negative carcinoma or molecular high-risk carcinoma, 18 years or older, in premenopausal women: negative pregnancy test, written consent
Exclusion criteria
Exclusion criteria: Diagnosis of another cancer type within the last 5 years (except: basalioma, in situ cervical cancer), contradictions to MRI, high grade renal insufficiency (GFR < 30 mg/dl), psychological disease or state, that disables the understanding of the study protocol, pregnancy and lactation period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the diagnostic accuracy of combined whole-body 18F-FDG-MR-PET for whole-body staging in breast cancer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of combined whole-body 18F-FDG-MR-PET and the diagnostic standard (according to the guideline: interdisziplinären S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms ) with regard to the diagnostic accuracy for whole-body tumor staging in breast cancer. | — |
Countries
Germany
Contacts
Public ContactChristian Buchbender
Universitätsklinikum Düsseldorf, Institut für Diagnostische und Interventionelle Radiologie
Outcome results
None listed